anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
Treatment of osteomyelitis is hampered by a paucity of evidence from prospective clinical trials with randomized treatment arms. Furthermore, previous randomized or observational trials have enrolled small numbers of subjects and thus often had non-definitive findings. One of the most common causes of osteomyelitis is Staphylococcus aureus. Over the past 10 years, rates of methicillin-resistant S. aureus (MRSA) have risen dramatically. Vancomycin is currently the treatment of choice for treating MRSA. While vancomycin is effective, it is only available in intravenous formulation and has renal and bone marrow toxicities. There is a critical need for effective, oral, cheap drugs for the treatment of MRSA. Trimethoprim-sulfamethoxazole (TMP-SMX) is a drug with several advantageous properties for the treatment of MRSA osteomyelitis. To address this question regarding optimal treatment of MRSA osteomyelitis, we designed a prospective, randomized trial comparing TMP-SMX with vancomycin for the treatment of MRSA osteomyelitis.
Recent trials suggested immediate complete revascularization (ICR) as a safe alternative to staged complete revascularization (SCR), but the impact of the respective percutaneous coronary intervention strategies between on- versus off-hours is unclear. On-hours was defined as an index revascularization performed between 8:00 a.m. and 6:00 p.m., Monday to Friday, or else the procedure was defined as performed during off-hours. The primary end point consisted of a composite of all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, and cerebrovascular events at 1-year follow-up. We used Cox regression models to relate randomized treatment with study end points. We evaluated multiplicative and additive interactions between on- versus off-hours and randomized treatment. The BIOVASC (Percutaneous Complete Revascularization Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease) trial enrolled 1,097 and 428 patients during on- and off-hours, respectively. Patients randomized during off-hours were more likely to present with ST-segment elevation myocardial infarction (66.4% vs 29.5%, p <0.001). The composite primary outcome occurred in 8.4% and 10.1% of patients randomized to ICR and SCR, respectively, during on-hours (hazard ratio 0.80, 95% confidence interval 0.54 to 1.19). During off-hours, the primary composite outcome occurred in 5.4% and 7.7% in ICR and SCR (0.69, 95% confidence interval 0.32 to 1.46) with no evidence of a differential effect (interaction pmultiplicative = 0.70, padditive = 0.56). No differential effect was found between treatment allocation and on- versus off-hours in any of the secondary outcomes. In conclusion, no differential treatment effect was found when comparing ICR versus SCR in patients presenting with acute coronary syndrome and multivessel disease during on- or off-hours.
In stage I eligible participants will be randomly assigned to either the standard interval (either 4 or 6 weeks) or the extended interval (either 8 or 12 weeks) following an initial 12 weeks of standard of care immunotherapy. Disease recurrence and survival will be assessed, along with quality of life and health economic outcomes. The trial includes a feasibility outcome by which recruitment feasibility will be assessed.

Immunotherapy drugs are a standard treatment option for advanced kidney cancer, melanoma, and some lung cancers. These drugs work by stimulating the body's own immune system to fight against cancer cells. Clinical trials have proven the effectiveness of immunotherapy drugs, such as ipilimumab, nivolumab or pembrolizumab, in the treatment of different cancers. However the best way to give these drugs is not known.
PCT No. PCT/GB95/01627 Sec. 371 Date Oct. 7, 1996 Sec. 102(e) Date Oct. 7, 1996 PCT Filed Jul. 11, 1995 PCT Pub. No. WO96/01619 PCT Pub. Date Jan. 25, 1996A bolus for delivery of pulsed doses of biologically active material to a ruminant comprises a series of distinct and separate bolus elements. Each bolus element is constructed of a degradable outer sheath and a core of biologically active material. The elements are adapted to separate following administration to the ruminant, and to disperse in the rumeno-reticular sac. In due course the elements degrade or corrode to release the biologically active material. Example boli include bolus elements of different respective corrosion characteristics and, as such, are capable of releasing pulsed doses of the active material to the ruminant.
The utility model relates to a tablet printed with dose dividing markers. The number of the dose dividing marker which is printed on the surface of one side of the tablet is >=1 so that the whole tablet is divided into at least two equal parts. The number of the dose dividing marker which is printed on the surface of the other side of the tablet is >=0 so that the whole tablet is divided into at least zero equal part. The tablet can be in shapes of circle, ring, rectangle, square, trapezoid, ellipse, capsule, triangle and regular polygon. The whole tablet can be taken by adults, and is particularly suitable for special patients such as children, the old and patients suffering from liver and kidney dysfunction due to the facts that doses of the tablet can be conveniently and quickly adjusted through the dose dividing markers printed on the surface of the tablet, deficiency of dose specifications of the tablets in the market can be made up and adverse drug reaction caused by inaccurate doses can be lessened. The tablet printed with the dose dividing markers is simple in structure, and the dose dividing markers can be printed on the surface of the tablet by the aid of existing tablet printing machines, so that cost is reduced, marking dies are not needed to purchase and a shortcoming that the marking dies are easily to be worn is avoided.
After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was maintained with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
The present invention relates to a traditional Chinese medicine sponge pill. Medicine powder and refined honey is agitated, charged, extruded, cut, etc. so as to cause the inner part of the pill to become porous, and thus, the traditional Chinese medicine pill becomes soft. The traditional Chinese medicine sponge pill is favorable to patients' administration, and contributes to the disintegration and the absorption of the pill in human bodies. Simultaneously, CO2, N2 or other inert gas is charged in small pores by the difference of processing methods. The oxygen lack environment caused by the charged gas can inhibit bacteria growth, and can extend the storage period of the traditional Chinese medicine. The method is used for producing traditional Chinese medicine ointment.
Participants will complete baseline survey instruments and again complete surveys after 4-6 months. They will then receive the video-based educational tablet.
All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
A method is provided that includes receiving measurements of biological elements from a blood sample of a patient. The respective biological elements are managed by the endocrine system, which is organizable in axes including a corticotropic axis, gonadotropic axis, thyreotropic axis and somatotropic axis. The method includes calculating a plurality of indexes as functions of the measurements. The indexes reflect physiological relationships between the biological elements and the hormones that manage the respective biological elements, and at least some of the indexes reflect physiological relationships between hormones across axes of the endocrine system. The method also includes evaluating the indexes by axis of the endocrine system to facilitate identification of one or more dysfunctions capable of participating in the genesis, installation and evolution of a pathology, and thereby formulate a diagnosis of the patient. And the method includes administering a therapy to the patient in accordance with the diagnosis.
Techniques for determining a device profile and anomalous behavior associated with a device in a network are disclosed. Attribute values associated with a target device are determined based on data packets detected from a network. A subset of a set of classifiers associated with the available attribute values are selected. The attribute values are applied to the selected classifiers to determine a respective candidate device profile. A current device profile is determined for the target device based on the candidate device profiles. The current device profile indicates expected attribute values for the target device. Current attribute values are compared to the expected attribute values to determine whether there is any anomalous behavior associated with the target device.
PURPOSE: To identify dosimetric predictive factors of sensorineural hearing loss (SNHL) in children after cranial radiation therapy (RT) in a single institution using dosimetric data from the French National Registry PediaRT.
METHODS AND MATERIALS: Complete audiological follow-up data were available for 44 children treated with cranial RT between 2014 and 2021 at our institution. The median age at the time of RT initiation was 9 years (range: 2-17 years). No children presented with hearing loss prior to treatment. SNHL was defined as a Chang ototoxicity grade ≥ 1a or higher.
RESULTS: Median audiometric follow-up duration was 51 months. Seven children (16 %) developed SNHL with a median time to occurrence of 33 months (range, 18-46 months). The estimated SNHL cumulative rate at 2 years post-RT was 4,5% ± 3,1% and at 5 years was 21 % ± 7.2 %. Multiple Cox regression models showed that the association of the age at radiotherapy and the dosimetric values to the inner ear canal and cochlea were the most significant predictive factors of SNHL occurrence. No child who received less than 35 Gy on average to both cochleae (n = 26) suffered from SNHL, whereas the 5-year SNHL cumulative incidence for the children who received greater than or equal to 35 Gy on average to either cochlea (n = 18) was 51.8 % ± 15.1 %.
CONCLUSION: Doses received by the inner ear canal and cochlea, associated with the age at RT initiation, are the main predictive factors for radiation-induced SNHL. A median dose to either cochlea over 35 Gy significantly increases the risk of SNHL and justify close audiometric monitoring to detect and equip hearing loss at an early stage.
After randomization to 48h after endovascular therapy, the target of BP was determined by clinicians according to current guidelines, i.e. \<180/105mmHg.
It has been discovered that the stimulation of .beta.-adrenergic receptors, which activate cAMP formation, gives rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising .beta.-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by .beta.-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP).  Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of .beta.-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
The purpose of this study is to see if Heart Rate Variability Biofeedback (HRV-B) can reduce chronic pain, stress, depression, anxiety, insomnia, loneliness, helplessness, physical limitations and pain medication dependence. HRV-B is an interactive procedure in which participants relax and breathe regularly while watching a computer screen. The computer screen provides feedback that helps people increase their heart rate variability, which is the difference from beat to beat. HRV-B is a complementary, non-pharmacologic therapy that is now being used to see if it can help sickle cell patients reduce their symptoms of pain, stress, insomnia, fatigue, or depression.

Participants will be randomly assigned to either an Intervention Group or a Comparison Group. Each group will have about 15-20 participants. The Intervention group will receive a baseline assessment including symptom questionnaires, up to six weekly HRV-B training sessions lasting about 45 minutes each, and a follow-up assessment including symptom questionnaires. There are 6-8 total visits for the intervention group and 2 for the control group. The Comparison Group will have a baseline assessment including symptom questionnaires, then six weeks with no training sessions, then a follow up assessment including symptom questionnaires. After the follow up assessment, the Comparison Group members will have the option of receiving the same treatment as the Intervention Group.
This study will evaluate the effects of unilateral knee pain on contralateral knee joint loading during different types of walking. Thirty adults with unilateral symptomatic knee osteoarthritis will complete four, 1.5-hour study visits. The first and third visits will include level, inclined, and declined walking at comfortable, fast, and slow speeds. The second and fourth visits will include a 30-minute walk. There will be at least two days between visits. The only difference between each pair of visits is that one visit will involve walking with unilateral knee pain (painful walking) and the other visit will involve walking without unilateral knee pain (nonpainful walking). Individuals will be recruited based on the presence of unilateral knee pain so the painful walking will be representative of their typical walking. For the visits with nonpainful walking, the third and fourth visits, pain will be alleviated by performing an intraarticular injection with a local anesthetic (lidocaine hydrochloride). All walking will be performed in a three-dimensional motion capture environment on a split-belt treadmill that is instrumented with force plates.

A cohort of 30 healthy individuals will complete the same walking conditions at two, 1.5-hour study visits. The healthy control group will not receive intraarticular knee injections. The purpose of this cohort is to better understand how walking mechanics in individuals with unilateral knee osteoarthritis compare to similar individuals without knee osteoarthritis.
The pathophysiological mechanism of cerebral ischemia/reperfusion injury (CIRI) is complex, and the current treatment methods are limited and the efficacy is not good. Previous therapeutic strategies of CIRI mostly target neurons, but no significant progress has been made. At present, astrocytes are expected to be promising effector cells for the treatment of CIRI. Astrocytes are a "double-edged sword" in the pathological process of CIRI, with both neurotoxic and neuroprotective effects on the central nervous system. How to effectively use astrocytes to treat CIRI has become a research hotspot. In this review, the dual roles of astrocytes in CIRI mechanism were reviewed, and the related mechanisms of astrocytes in relieving oxidative stress induced by CIRI were emphasized, in order to provide new ideas for the treatment of CIRI.
PURPOSE:To remove endotoxin from yarn contg. the endotoxin by bringing an endotoxin adsorbing and removing agent contg. a water-insoluble calcium salt as an effective component into this yarn to adsorb the endotoxin on this adsorbing and removing agent, then separating the adsorbing agent and the yarn or removing the adsorbing agent from the yarn. CONSTITUTION:This endotoxin adsorbing and removing agent is composed by incorporating the water-insoluble calcium salt (e.g. calcium carbonate) as an effective component therein. This endotoxin adsorbing and removing agent is brought into contact with the yarn contg. the endotoxin to adsorb the endotoxin on the adsorbing and removing agent and thereafter, the adsorbing and removing agent and the yarn are separated or the adsorbing and removing agent is removed from the yarn, by which the endotoxin is removed from the yarn. A sodium chloride is added to the endotoxin adsorbing and removing agent in such a manner that its content attains 0.001 to 20.0wt.%. Consequently, the endotoxin is effectively removed from the yarn contg. the endotoxin harmful for living things.
The electrostatic chuck (620) attracts an object (680) such as a pharmaceutical tablet or pharmaceutical particles. The chuck has a floating electrode thereby providing for charge imaging for the deposition particles in a selected image. A sensing electrode senses the number of particles attracted to the objects on the chuck thus ensuring that an accurate amount is deposited. The lower conductive layer (610) of the chuck is coated with a dielectric layer (630), on top of which is an upper conductive layer (640) with two electrodes (650, 660). A second dielectric layer (670) is placed on top of the upper conductive layer (640). A voltage between 200 and 2000 volts, either DC or AC, is applied across the two electrodes of the chuck
Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
Individuals over 50 years of age who have developed new-onset diabetes mellitus (diagnosed within the past 12 months) or deteriorating diabetes will be recruited through the offices of primary care physicians and endocrinologists. Those meeting initial criteria will meet with a research APRN and will undergo a secondary screen to determine eligibility. Individuals enrolled in the study will undergo a five-minute psychological survey and donation of a blood sample for bio-bank analysis every 6 months for 3 years. MRI will be performed at baseline. Any abnormalities on MRI will be reviewed by a multi-disciplinary tumor board and discussed with the participant. Additional MRI will be performed on case-by-case basis
Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
Many adults with sickle cell disease experience chronic, nonvaso-occlusive pain that can benefit from nonpharmacological interventions available for use in the home setting. Virtual reality (VR) has been shown to be effective in decreasing pain in chronic pain conditions and may be useful for home-based self-management of chronic pain in sickle cell. However, the literature lacks studies examining this potential. Additionally, the knowledge and experiences of adults with sickle cell who have tried VR for home-based chronic pain management have not yet been reported. This qualitative, descriptive pilot study explored the knowledge and perceptions of VR among adults with sickle cell and their experience with using in-home VR for chronic pain. Nine participants completed demographic questionnaires and an individual interview that was recorded, transcribed verbatim, and analyzed using thematic analysis. Participants were 21 to 38 years of age, and most were female (88.9%) with a medium or high sickle cell disease severity (88.9%) and a chronic pain-grade classification of grade III (high disability-moderately limiting) or grade IV (high disability-severely limiting) (55.5%). Interview themes, which aligned with the technology acceptance model, were 1) pain beliefs and self-management, 2) VR as another world, and 3) experience of using in-home VR. Based on preliminary data, VR shows promise as a strategy for nonpharmacological management of chronic pain in adults with sickle cell. However, further investigations are warranted to mitigate the challenges and limitations associated with using VR in this capacity. PERSPECTIVE: Few evidence-based, nonpharmacological interventions exist for chronic pain in adults with sickle cell disease. This first qualitative, pilot study of in-home VR for chronic pain in adults with sickle cell disease suggests that VR interventions need further exploration as a nonpharmacological strategy for mitigating their pain in the home setting.
INTRODUCTION: While supported by robust evidence and decades of clinical experience, right ventricular apical pacing for bradycardia is associated with a risk of progressive left ventricular dysfunction. Cardiac resynchronization therapy for heart failure with reduced ejection fraction can result in limited electrical resynchronization due to anatomical constraints and epicardial stimulation. In both settings, directly stimulating the conduction system below the atrio-ventricular node (either the bundle of His or the left bundle branch area) has potential to overcome these limitations. Conduction system pacing has met with considerable enthusiasm in view of the more physiological electrical conduction pattern, is rapidly becoming the preferred option of pacing for bradycardia, and is gaining momentum as an alternative to conventional biventricular pacing.
AREAS COVERED: This article provides a review of the current efficacy and safety data for both people requiring treatment for bradycardia and the management of heart failure with conduction delay and discusses the possible future roles for conduction system pacing in routine clinical practice.
EXPERT OPINION: Conduction system pacing might be the holy grail of pacemaker therapy without the disadvantages of current approaches. However, hypothesis and enthusiasm are no match for robust data, demonstrating at least equivalent efficacy and safety to standard approaches.